# Valganciclovir in Patients With CMV Retinitis and AIDS Who Cannot Take Drugs by Injection

> **NCT00017784** · PHASE3 · UNKNOWN · sponsor: **Hoffmann-La Roche** · enrollment: 500 (—)

## Conditions studied

- Cytomegalovirus Retinitis
- HIV Infections

## Interventions

- **DRUG:** Valganciclovir

## Key facts

- **NCT ID:** NCT00017784
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 500 (—)
- **Last updated:** 2005-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00017784

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00017784, "Valganciclovir in Patients With CMV Retinitis and AIDS Who Cannot Take Drugs by Injection". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00017784. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*